Evidence map›Paper›PMID 29352259›Full record

ArticleScientific reports2018

Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up Study.

Wei-Ju Lee, Yi-Chu Liao, Yen-Feng Wang, I-Feng Lin, Shuu-Jiun Wang, Jong-Ling Fuh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 7 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 7 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Correlation between MCP-1-2518A/G polymorphism and the risk of Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Neuroinflammation and Disease: Pathways and Opportunities.Annual review of pharmacology and toxicology · 2026
    Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wei-Ju LeeNeurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan.
Yi-Chu LiaoFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Yen-Feng WangFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
I-Feng LinInstitute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Shuu-Jiun WangFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. sjwang@vghtpe.gov.tw.
Jong-Ling FuhFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. jlfuh@vghtpe.gov.tw.ORCID http://orcid.org/0000-0001-9135-3351
National Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monocyte chemoattractant protein-1 (MCP-1, also known as chemokine CCL2) is a vital chemokine that mediates inflammation in Alzheimer's disease (AD). We analyzed the associations between the baseline plasma MCP-1 level, longitudinal cognitive changes, and genetic effects of CCL2 rs1024611 and its receptor, CC-chemokine receptor 2 (CCR2) rs1799864, in AD. In total, 310 AD patients and 66 mild cognitive impairment (MCI) patients were followed for 2 years, and 120 controls were recruited at baseline for comparison. After adjusting for covariates using one-way analysis of covariance, AD patients had higher plasma MCP-1 levels compared with MCI patients and controls, and severe AD patients had the highest levels. After adjusting for covariates using generalized estimating equation analysis, the results showed that the baseline MCP-1 level was significantly correlated with changes in the two-year Mini-Mental Status Examination (p = 0.046). The A allele of CCR2 rs1799864 was associated with a higher MCP-1 level in AD and MCI patients. In conclusion, plasma MCP-1 might reflect the risk and disease course of AD. A higher plasma MCP-1 level is associated with greater severity and faster cognitive decline. Additionally, the CCR2 polymorphism may play a role in the regulation of MCP-1/CCR2 signaling in AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBiomarkersCase-Control StudiesChemokine CCL2Cognitive DysfunctionFemaleHumansMalePolymorphism, Single NucleotideReceptors, CCR2BiomarkersCCL2 protein, humanCCR2 protein, humanChemokine CCL2Receptors, CCR2

Identifiers

PMID29352259
PMCPMC5775300
OpenAlexW2782565874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.